> ## Content Index
> Fetch the complete content index at: https://www.coios.me/llms.txt
> Use this file to discover other available public pages before exploring further.

# Lecanemab in Chinese patients with Alzheimer's disease over 13 months of routine care
- URL: https://www.coios.me/lecanemab-in-chinese-patients-with-alzheimer-s-disease-over/
- Published: 2026-11-19T13:00:12.000Z
- Updated: 2026-11-19T16:04:15.000Z
- Description: Among 122 Chinese patients with Alzheimer's disease treated with lecanemab, 84% held or improved their Clinical Dementia Rating stage at 13 months and two-thirds became amyloid-negative, but those whose amyloid fell most did not clearly improve most in cognition.
- Author: Daniel Ryan
- Tags: Health today, Dementia, China, #peer-reviewed, #refines, #item, #source-2026-11, #score-60

This prospective cohort followed 122 patients given lecanemab every two weeks at nine centres in Southwest China. Of these, 38.52% had mild cognitive impairment due to Alzheimer's disease (AD) and 40.98% had mild AD dementia. Treated patients had more favourable cognitive trajectories than propensity-matched local controls and an Alzheimer's Disease Neuroimaging Initiative natural-history cohort. At 13 months, 84.00% held or improved their Clinical Dementia Rating stage and 66.67% became amyloid-negative (Centiloid below 12). Amyloid reduction was not robustly linked to cognitive gain, and baseline clinical variables did not reliably predict response. Amyloid-related imaging abnormalities affected 10.66%, and the abstract does not say how many patients reached 13 months.

*Why it is interesting: It adds 13-month real-world data on an anti-amyloid drug outside trial populations. Patients stopped mostly because repeated infusions were inconvenient, not because of safety concerns.*

Source

[Journal of Neurology, 18 November 2026](https://doi.org/10.1007/s00415-026-14270-6?ref=coios.me)

Paper

Thirteen-month real-world effectiveness and safety of lecanemab in Chinese patients with Alzheimer’s disease: integrating objective clinical outcomes and caregiver-reported experiences

Authors

Chen S, Gao X, Li F, Ou R, Wei Q, Li C et al.

DOI

10.1007/s00415-026-14270-6

Type

Peer-reviewed article

Design

Prospective multicentre observational cohort, 122 lecanemab-treated patients across nine centres in Southwest China, 222 follow-up visits over 13 months, propensity-matched local and ADNI controls

Verdict

Refines prior evidence

Driver

[Dementia](https://www.coios.me/d-dementia/)